person · Reporting owner

Leuthner Brian A

Disclosed activity across 2 companies

Tapewire entity: 137779
SEC CIK: 0001652973

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ONCOSEC MEDICAL IncONCS · Entity 117092	Interim CEO	June 28, 2021	June 29, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ONCOSEC MEDICAL Inc

Report date June 28, 2021 · Filed June 29, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	178,387	Ending reported balance After 2021-06-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-06-28 · Grant · Acquired 192,000 · Balance 192,000 F1: Reflects restricted stock units (RSUs) that were 25% vested upon grant with the remaining 75% vesting in equal quarterly installments over the next two years. Row 2 · 2021-06-28 · Sale · Disposed 13,613 · Balance 178,387 F2: In connection with the vesting of 48,000 RSUs on June 28, 2021, a total of 13,613 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2031-06-28	Direct	33,000	Reported balance After 2021-06-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-28 · Grant · Acquired 33,000 · Balance 33,000 F3: The option is 25% vested upon grant with the remaining 75% vesting in equally in quarterly installments over the next two years.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects restricted stock units (RSUs) that were 25% vested upon grant with the remaining 75% vesting in equal quarterly installments over the next two years.

F2: In connection with the vesting of 48,000 RSUs on June 28, 2021, a total of 13,613 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies.

F3: The option is 25% vested upon grant with the remaining 75% vesting in equally in quarterly installments over the next two years.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Section 16 reporting ended · disclosed 2019-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	239,268	Reported balance After 2019-03-15 transaction · row 1 1 source row Row 1 · 2019-03-15 · Exercise / conversion · Acquired 169,032 · Balance 239,268 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-03-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-03-15 · Exercise / conversion · Disposed 169,032 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F6: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F7: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.
Common StockSEC Table I · non-derivative	Indirect401(K) Plan	8,493.85	Reported balance Holding disclosure · report date 2019-03-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 8,493.85 F2: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.
Common StockSEC Table I · non-derivative	IndirectBy Spouse	162,000	Reported balance Holding disclosure · report date 2019-03-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 162,000 F3: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	223,622	Reported balance Holding disclosure · report date 2019-03-15 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 223,622 F4: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.

F3: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F5: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F6: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F7: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 28, 2021 Filed Jun 29, 2021 19:42 UTC	ONCOSEC MEDICAL Inc ONCS · Entity 117092	GrantStock Option (Right to Buy) · Derivative	33,000	$0.00 Strike: $3.16	$0.00	Disclosure SEC source: 0001493152-21-015620 · ownership.xml · derivative · entry 3 Leuthner Brian A · CIK 0001652973 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2031-06-28 F3 · derivative.exercise_date: The option is 25% vested upon grant with the remaining 75% vesting in equally in quarterly installments over the next two years. Read SEC document
June 28, 2021 Filed Jun 29, 2021 19:42 UTC	ONCOSEC MEDICAL Inc ONCS · Entity 117092	SaleCommon Stock	13,613	$3.16	$43,017.08	Disclosure SEC source: 0001493152-21-015620 · ownership.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,387 F2 · shares: In connection with the vesting of 48,000 RSUs on June 28, 2021, a total of 13,613 shares were sold in order to satisfy the reporting person's tax withholding obligations. This sale occurred automatically, and the amount sold corresponded to the tax withholding amount. The reporting person had no control with respect to such sale, which was conducted in accordance with the Issuer's corporate policies. Read SEC document
June 28, 2021 Filed Jun 29, 2021 19:42 UTC	ONCOSEC MEDICAL Inc ONCS · Entity 117092	GrantCommon Stock	192,000	$0.00	$0.00	Disclosure SEC source: 0001493152-21-015620 · ownership.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 F1 · shares: Reflects restricted stock units (RSUs) that were 25% vested upon grant with the remaining 75% vesting in equal quarterly installments over the next two years. Read SEC document
February 02, 2021 Filed Feb 17, 2021 17:05 UTC	ONCOSEC MEDICAL Inc ONCS · Entity 117092	GrantStock Option(Right to Buy) · Derivative	150,000	$0.00 Strike: $7.45	$0.00	Disclosure SEC source: 0001493152-21-004162 · ownership.xml · derivative · entry 1 Leuthner Brian A · CIK 0001652973 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-02 F1 · date: The option was 25% vested on February 2, 2021 and the remaining options vest quarterly over a two-year period. Read SEC document
March 15, 2019 Filed Mar 18, 2019 17:44 UTC	PDS Biotechnology Corp EDGE · Entity 7939	Exercise / conversionRestricted Stock Units · Derivative	169,032	$0.00	$0.00	Disclosure SEC source: 0001127602-19-011924 · form4.xml · derivative · entry 5 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,032 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F6 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F7 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document
March 15, 2019 Filed Mar 18, 2019 17:44 UTC	PDS Biotechnology Corp EDGE · Entity 7939	Exercise / conversionCommon Stock	169,032	$0.00	$0.00	Disclosure SEC source: 0001127602-19-011924 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. Read SEC document
August 14, 2018 Filed Aug 15, 2018 07:43 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantRestricted Stock Units · Derivative	169,032	$0.00	$0.00	Disclosure SEC source: 0001127602-18-025357 · form4.xml · derivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,032 Underlying: Common Stock · 169,032 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document
June 19, 2018 Filed Jun 20, 2018 16:22 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantStock Option (Right To Purchase) · Derivative	338,068	$0.00 Strike: $1.10	$0.00	Disclosure SEC source: 0001127602-18-021574 · form4.xml · derivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,068 Underlying: Common Stock · 338,068 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document
March 02, 2018 Filed Mar 5, 2018 08:19 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$15.08	$37,700.00	Disclosure SEC source: 0001127602-18-009804 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.79 to $15.31 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 01, 2018 Filed Mar 5, 2018 08:19 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantStock Option (Right To Purchase) · Derivative	280,000	$0.00 Strike: $14.98	$0.00	Disclosure SEC source: 0001127602-18-009804 · form4.xml · derivative · entry 5 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2028-03-01 F6 · derivative.exercise_date: This option, representing a right to purchase a total of 280,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document
March 01, 2018 Filed Mar 5, 2018 08:19 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$14.81	$37,025.00	Disclosure SEC source: 0001127602-18-009804 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.29 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 23, 2018 Filed Feb 23, 2018 17:28 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$15.37	$38,425.00	Disclosure SEC source: 0001127602-18-008091 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.92 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 22, 2018 Filed Feb 23, 2018 17:28 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$15.47	$38,675.00	Disclosure SEC source: 0001127602-18-008091 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.75 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 02, 2018 Filed Feb 2, 2018 21:15 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$12.96	$32,400.00	Disclosure SEC source: 0001127602-18-003874 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $12.78 to $13.06 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 01, 2018 Filed Feb 2, 2018 21:15 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$13.14	$32,850.00	Disclosure SEC source: 0001127602-18-003874 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $12.68 to $13.45 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 03, 2018 Filed Jan 3, 2018 18:48 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.11	$25,275.00	Disclosure SEC source: 0001127602-18-000813 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.21 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 02, 2018 Filed Jan 3, 2018 18:48 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.11	$25,275.00	Disclosure SEC source: 0001127602-18-000813 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.45 to $10.45 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 05, 2017 Filed Dec 5, 2017 17:39 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$9.68	$24,200.00	Disclosure SEC source: 0001127602-17-033971 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.46 to $9.87 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 04, 2017 Filed Dec 5, 2017 17:39 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$9.97	$24,925.00	Disclosure SEC source: 0001127602-17-033971 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.37 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 01, 2017 Filed Dec 5, 2017 17:39 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$9.92	$24,800.00	Disclosure SEC source: 0001127602-17-033971 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.70 to $10.06 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 03, 2017 Filed Nov 3, 2017 17:53 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.86	$27,150.00	Disclosure SEC source: 0001127602-17-031249 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.02 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 02, 2017 Filed Nov 3, 2017 17:53 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.94	$27,350.00	Disclosure SEC source: 0001127602-17-031249 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $11.08 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 01, 2017 Filed Nov 3, 2017 17:53 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.92	$27,300.00	Disclosure SEC source: 0001127602-17-031249 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.40 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 04, 2017 Filed Oct 4, 2017 17:52 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$11.14	$27,850.00	Disclosure SEC source: 0001127602-17-029259 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $11.07 to $11.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 03, 2017 Filed Oct 4, 2017 17:52 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.93	$27,325.00	Disclosure SEC source: 0001127602-17-029259 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.09 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 02, 2017 Filed Oct 4, 2017 17:52 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.81	$27,025.00	Disclosure SEC source: 0001127602-17-029259 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.70 to $10.90 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 06, 2017 Filed Sep 6, 2017 20:01 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.31	$25,775.00	Disclosure SEC source: 0001127602-17-027107 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.56 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 05, 2017 Filed Sep 6, 2017 20:01 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$9.94	$24,850.00	Disclosure SEC source: 0001127602-17-027107 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.81 to $10.18 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 01, 2017 Filed Sep 6, 2017 20:01 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.37	$25,925.00	Disclosure SEC source: 0001127602-17-027107 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.60 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 03, 2017 Filed Aug 3, 2017 20:45 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.40	$26,000.00	Disclosure SEC source: 0001127602-17-024929 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.61 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 02, 2017 Filed Aug 3, 2017 20:45 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.53	$26,325.00	Disclosure SEC source: 0001127602-17-024929 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.41 to $10.72 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 01, 2017 Filed Aug 3, 2017 20:45 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.65	$26,625.00	Disclosure SEC source: 0001127602-17-024929 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.54 to $10.85 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 06, 2017 Filed Jul 6, 2017 17:50 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.08	$25,200.00	Disclosure SEC source: 0001127602-17-023286 · form4.xml · nonDerivative · entry 3 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.22 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 05, 2017 Filed Jul 6, 2017 17:50 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.21	$25,525.00	Disclosure SEC source: 0001127602-17-023286 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,236 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.10 to $10.33 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 03, 2017 Filed Jul 6, 2017 17:50 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	2,500	$10.27	$25,675.00	Disclosure SEC source: 0001127602-17-023286 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,736 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.07 to $10.48 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
April 26, 2017 Filed May 9, 2017 15:33 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	100	$11.10	$1,110.00	Disclosure SEC source: 0001127602-17-017360 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,236 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
March 13, 2017 Filed Mar 15, 2017 15:30 UTC	PDS Biotechnology Corp EDGE · Entity 7939	GrantStock Option (right To Purchase) · Derivative	267,500	$8.86 Strike: $8.86	$2,370,050.00	Disclosure SEC source: 0001127602-17-011765 · form4.xml · derivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,500 Underlying: Common Stock · 267,500 shares Expires 2027-03-13 F1 · derivative.exercise_date: This option, representing a right to purchase a total of 267,500 shares of Common Stock, will become exercisable on February 17, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date. Read SEC document
February 07, 2017 Filed Feb 8, 2017 15:53 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	1,500	$9.52	$14,280.00	Disclosure SEC source: 0001127602-17-004564 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,479 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.62 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 06, 2017 Filed Feb 7, 2017 16:12 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	1,500	$9.52	$14,280.00	Disclosure SEC source: 0001127602-17-004341 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,979 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.59 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 03, 2017 Filed Feb 7, 2017 16:12 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	1,500	$9.69	$14,535.00	Disclosure SEC source: 0001127602-17-004341 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,479 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.82 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 02, 2017 Filed Feb 3, 2017 15:25 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	1,500	$9.61	$14,415.00	Disclosure SEC source: 0001127602-17-003847 · form4.xml · nonDerivative · entry 2 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,979 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.46 to $9.80 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 01, 2017 Filed Feb 3, 2017 15:25 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	1,500	$9.38	$14,070.00	Disclosure SEC source: 0001127602-17-003847 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,479 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $9.16 to $9.63 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 01, 2016 Filed Dec 2, 2016 15:00 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	7,500	$11.60	$87,000.00	Disclosure SEC source: 0001127602-16-068954 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,979 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $11.11 to $12.35 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 03, 2016 Filed Oct 4, 2016 11:16 UTC	PDS Biotechnology Corp EDGE · Entity 7939	SaleCommon Stock	7,500	$10.25	$76,844.25	Disclosure SEC source: 0001127602-16-063859 · form4.xml · nonDerivative · entry 1 Leuthner Brian A · CIK 0001652973 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,479 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $10.02 to $10.53 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.